SHIM
TVTX icon

Stone House Investment Management’s Travere Therapeutics TVTX Stock Holding History

Stone House Investment Management’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.44K Hold
43
– – ﹤0.01% 698
2026
Q1 		$1.28K Hold
43
– – ﹤0.01% 669
2025
Q4 		$1.64K Buy
43
+5
+13% +$163 ﹤0.01% 576
2025
Q3 		$908 Buy
+38
New +$714 ﹤0.01% 571

Other funds holding TVTX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $9.33B AUM 56.1% 1-Year Est. Return
EA
Emerald Advisers Leola, Pennsylvania $4.25B AUM 141.71% 1-Year Est. Return
EMFAT
Emerald Mutual Fund Advisers Trust Leola, Pennsylvania $2.85B AUM 140.52% 1-Year Est. Return
Fiera Capital (Canada)
Fiera Capital (Canada) Montreal, Quebec, Canada $27.6B AUM 23.56% 1-Year Est. Return
PAM
Panagora Asset Management Boston, Massachusetts $32.6B AUM 52.29% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $114B AUM 41.71% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return

Stone House Investment Management's TVTX Position: Q2 2026 in Review

Stone House Investment Management held its Travere Therapeutics (TVTX) position steady in Q2 2026 at 43 shares worth $2.44K. The position accounts for ﹤0.01% of the portfolio, ranked #698.

Stone House Investment Management first reported a position in TVTX in Q3 2025 and has held it in 4 quarters since. 110 funds tracked by Wall St. Rank hold TVTX as of Q2 2026.

  • Stone House Investment Management held 43 shares of Travere Therapeutics worth $2.44K as of Q2 2026.
  • Stone House Investment Management left its Travere Therapeutics share count unchanged in Q2 2026.
  • Travere Therapeutics made up ﹤0.01% of Stone House Investment Management's portfolio in Q2 2026, its #698 holding.
  • Stone House Investment Management first reported a position in Travere Therapeutics in Q3 2025 and has held it in 4 quarters since.
  • 110 funds tracked by Wall St. Rank held Travere Therapeutics as of Q2 2026.

Based on Stone House Investment Management's 13F filing for Q2 2026, filed 5 Aug 2026.